These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32542389)

  • 1. Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR.
    Dhoonmoon A; Schleicher EM; Clements KE; Nicolae CM; Moldovan GL
    Nucleic Acids Res; 2020 Jul; 48(13):7252-7264. PubMed ID: 32542389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy.
    Schneider HE; Schmitt LM; Job A; Lankat-Buttgereit B; Gress T; Buchholz M; Gallmeier E
    Neoplasia; 2024 Nov; 57():101038. PubMed ID: 39128273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress.
    Nicolae CM; Aho ER; Choe KN; Constantin D; Hu HJ; Lee D; Myung K; Moldovan GL
    Nucleic Acids Res; 2015 Mar; 43(6):3143-53. PubMed ID: 25753673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extending ATR-CHK1 circuitry: the replication stress response and beyond.
    Simoneau A; Zou L
    Curr Opin Genet Dev; 2021 Dec; 71():92-98. PubMed ID: 34329853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response.
    Lin YF; Shih HY; Shang Z; Matsunaga S; Chen BP
    Nucleic Acids Res; 2014 Apr; 42(7):4463-73. PubMed ID: 24500207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage.
    Gupta D; Lin B; Cowan A; Heinen CD
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1523-1528. PubMed ID: 29378956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
    Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
    Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
    Ngoi NYL; Pham MM; Tan DSP; Yap TA
    Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
    Mei L; Zhang J; He K; Zhang J
    J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
    Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
    Liu K; Graves JD; Lin FT; Lin WC
    J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Activity Fine-tunes the DNA Replication Choreography of Chk1-depleted Cells.
    Calzetta NL; González Besteiro MA; Gottifredi V
    J Mol Biol; 2021 May; 433(10):166949. PubMed ID: 33744317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
    Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
    Mutat Res; 2023; 827():111834. PubMed ID: 37531716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
    Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.